Objective
To study whether the expression of biological factors is related to breast cancer changes during neoadjuvant chemotherapy, and to explore the clinical significance of such changes. To analyze whether the Miller-Payne grading of breast cancer after neoadjuvant chemotherapy is related to the expression of biological factors, so as to provide ideas for predicting the effects of neoadjuvant chemotherapy in different patients.
Methods
All 68 cases who accepted the preoperative neoadjuvant chemotherapy of breast cancer in our hospital from January 2019 to May 2021 were collected in this analysis. Significant changes of the expression of the endoplasmic reticulum ER, PR, Her-2, Ki-67 before and after the neoadjuvant chemotherapy were analyzed by the immunohistochemistry. Pathological Miller-Payne grading system evaluation was performed after chemotherapy, and the relationship between Miller-Payne grading system and the expression of biological factors ER, PR, Her-2 and Ki-67 in breast cancer before chemotherapy was analyzed.
Results
The positive rate of Ki-67 in 68 patients decreased to 34.1% after neoadjuvant chemotherapy compared with the prior 65.9%, which is statistically significant (P< 0.05). 15 (22.1%) patients had a grade 5 (G5) response after the neoadjuvant chemotherapy. There was a statistical difference in the expression of Her-2 between the G5 and G1 ~ 4 groups (P< 0.05). The results of the logistic regression analysis showed that the positive expression of Her-2 was a predictor for G5 in breast cancer treated with neoadjuvant chemotherapy [P< 0.05,OR= 0.214, 95%CI(0.056 ~ 0.816)].
Conclusion
The expression of Ki-67dose is significantly lowered in breast cancer patients after neoadjuvant chemotherapy, which can be used as a sensitive index for clinical chemotherapy evaluation. The positive expression of Her-2 can be used as a predictor of Miller-Payne grading (G5) in breast cancer patients treated with neoadjuvant chemotherapy.